➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Medtronic
Mallinckrodt
Colorcon
AstraZeneca

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,537,620

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,537,620
Title:Site-specific polyethylene glycolylated (pegylated) asparaginase, preparation method therefor and use thereof
Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde group serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
Inventor(s): Ma; Bruce Yong (Changzhou, CN), Wang; Jun (Changzhou, CN), Wang; He (Changzhou, CN), Xu; Chunlin (Changzhou, CN), Chen; Yifei (Changzhou, CN), Wang; Yaofang (Changzhou, CN)
Assignee: ZONHON BIOPHARMA INSTITUTE INC. (Changzhou, CN) GENSUN INSTITUTE OF BIOMEDICINE CO., LTD. (Changzhou, CN)
Application Number:15/522,445
Patent Claims:1. A site-specific di-polyethylene glycolylated (diPEGylated) L-asparaginase or a pharmaceutically acceptable salt or complex thereof, wherein each of N-terminal aminos of 2 out of 4 subunits of the diPEGylated L-asparaginase is coupled to one polyethylene glycol (PEG) molecule separately, wherein the PEG molecule prior to coupling to the L-asparaginase is branched and has a molecular weight of 30-40 KDa, and wherein the diPEGylated L-asparaginase has the general structural formula below: ##STR00004## wherein R is H or a C1-C4 alkyl, n is an integer from 320 to 455, P is an integer from 1 to 4, AA is an N-terminal L-amino acid residue, m is an integer from 0 to 5, S is 2, and ASP is L-asparaginase.

2. The site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 1, wherein R is methyl, n is an integer from 320 to 455, P is 2, and m is 0.

3. The site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 1, wherein the PEG prior to coupling to the L-asparaginase has an aldehyde group serving as an activating group.

4. The site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 3, wherein the aldehyde group is acetaldehyde, propionaldehyde, butyraldehyde, or valeraldehyde.

5. A pharmaceutical composition, comprising the site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 1, and a pharmaceutically acceptable adjuvant.

6. The pharmaceutical composition according to claim 5, which is in the dosage form of a freeze-dried powder injection.

7. A method for preparing the site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 1, comprising: step 1: formulating a 15-20 mg/mL L-asparaginase solution in 40 mM acetic acid-sodium acetate buffer pH 5.0; step 2: reacting for 12-24 hours at 4.degree. C. at a molar ratio of L-asparaginase:PEG:reducing agent=1:(4-5):(100-200); and step 3: purifying by ion exchange chromatography after reaction, to finally obtain the diPEGylated L-asparaginase according to claim 1, wherein the reducing agent of step 2 is sodium cyanoborohydride, and wherein the PEG of step 2 has the general structural formula below: ##STR00005## wherein R is H or a C1-C4 alkyl, n is an integer from 320 to 455, and P is an integer from 1 to 4.

8. A method for treating tumors in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of the site-specific diPEGylated L-asparaginase or pharmaceutically acceptable salt or complex thereof according to claim 1.

9. The method according to claim 8, wherein the tumors include acute lymphoblastic leukemia (ALL) tumors, NK/T cell lymphoma tumors, Hodgkin's disease tumors, acute myeloid leukemia tumors, acute myelomonocytic leukemia tumors, chronic lymphocytic leukemia tumors, lymphosarcoma tumors, reticulum cell sarcoma tumors, or melanotic sarcoma tumors.

10. A method for treating tumors in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of the pharmaceutical composition according to claim 5.

11. The method according to claim 10, wherein the tumors include acute lymphoblastic leukemia (ALL) tumors, NK/T cell lymphoma tumors, Hodgkin's disease tumors, acute myeloid leukemia tumors, acute myelomonocytic leukemia tumors, chronic lymphocytic leukemia tumors, lymphosarcoma tumors, reticulum cell sarcoma tumors, or melanotic sarcoma tumors.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
China2014 1 0837456Dec 29, 2014
PCT Information
PCT FiledFebruary 03, 2015PCT Application Number:PCT/CN2015/072167
PCT Publication Date:July 07, 2016PCT Publication Number:WO2016/106941

Details for Patent 10,537,620

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial ZONHON BIOPHARMA INSTITUTE INC. (Changzhou, CN) GENSUN INSTITUTE OF BIOMEDICINE CO., LTD. (Changzhou, CN) 2034-12-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
AstraZeneca
Express Scripts
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.